The review emphasizes that differing CLSI and EUCAST breakpoints complicate AMR tracking, calling for standardized criteria ...

Opportunities in the Next Generation Cancer Diagnostics Market include leveraging advancements in genomic and proteomic ...

JA Rosenfeld is an employee of Signature Genomic Laboratories, a subsidiary of PerkinElmer, Inc. The authors have no other relevant affiliations or financial involvement with any organization or ...

A structural aberration (SA) with secondary implications (SASIs) involving a cancer susceptibility gene is identified on chromosome microarray in approximately 0.6% tests performed on index cases.

A recent study on DNA microarray technology highlights its essential role in enabling high-throughput analysis of large numbers of genes through arrays of probes integrated on a solid-phase support.

An 8-year-old previously healthy female presents to the pediatrician’s office to establish care after recently moving to the United States from Peru 3 months ago. Past medical history is significant ...

Study of 99 pediatric patients found clinically significant CNVs in 30% of cases, supporting CMA as a first-tier test for developmental delay and ID. Clinically significant CNVs were identified in 30% ...

Stem cells and organoids are revolutionising medical advancements. The journey from stem cell research to translational medicine is extensive, and maintaining quality throughout development and ...

In a pair of papers, scientists greatly expanded our catalog of known genomic variation among humans. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it ...

Background: At present, there are few reports on 9q21.13 microdeletion syndrome, which is characterized by intellectual disability, epilepsy, autistic behaviour, and recognizable facial features, etc.